References
1. Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute
respiratory tract infection in adults: advice for high-value care from
the American College of Physicians and the Centers for Disease Control
and Prevention. Annals of Internal Medicine 2016;164:425-34.
2. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR
testing in coronavirus disease 2019 (COVID-19) in China: a report of
1014 cases. Radiology 2020:200642.
3. Li D, Wang D, Dong J, et al. False-negative results of real-time
reverse-transcriptase polymerase chain reaction for severe acute
respiratory syndrome coronavirus 2: role of deep-learning-based CT
diagnosis and insights from two cases. Korean journal of radiology
2020;21:505-8.
4. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical
2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology
2020:200343.
5. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19:
comparison to RT-PCR. Radiology 2020:200432.
6. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of
hospitalized patients with COVID-2019. Nature 2020:1-5.
7. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different
types of clinical specimens. Jama 2020.
8. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in
patients of novel coronavirus disease 2019. 2020.
9. Long C, Xu H, Shen Q, et al. Diagnosis of the Coronavirus disease
(COVID-19): rRT-PCR or CT? European journal of radiology 2020:108961.
10. Sun Y, Koh V, Marimuthu K, et al. Epidemiological and clinical
predictors of COVID-19. Clinical Infectious Diseases 2020.
11. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for
SARS-CoV-2 Infection—Challenges and Implications. New England Journal
of Medicine 2020.
12. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation
in False-Negative Rate of Reverse Transcriptase Polymerase Chain
Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. Annals of
Internal Medicine 2020.
13. Pulia MS, O’Brien TP, Hou PC, Schuman A, Sambursky R. Multi-Tiered
Screening and Diagnosis Strategy for COVID-19: A Model for Sustainable
Testing Capacity in Response to Pandemic. Annals of Medicine 2020:1-20.
14. Dahler-Eriksen BS, Lauritzen T, Lassen JF, Lund ED, Brandslund I.
Near-patient test for C-reactive protein in general practice: assessment
of clinical, organizational, and economic outcomes. Clinical chemistry
1999;45:478-85.
15. Diederichsen HZ, Skamling M, Diederichsen A, et al. Randomised
controlled trial of CRP rapid test as a guide to treatment of
respiratory infections in general practice. Scandinavian journal of
primary health care 2000;18:39-43.
16. Hansson LO, Carlsson I, Hansson E, Hovelius B, Svensson P, Tryding
N. Measurement of C-reactive protein and the erythrocyte sedimentation
rate in general practice. Scandinavian journal of primary health care
1995;13:39-45.
17. Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant
GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate,
and C-reactive protein to a diagnosis of pneumonia in acute lower
respiratory tract infection. The British journal of general practice :
the journal of the Royal College of General Practitioners
2003;53:358-64.
18. Lindback S, Hellgren U, Julander I, Hansson LO. The value of
C-reactive protein as a marker of bacterial infection in patients with
septicaemia/endocarditis and influenza. Scandinavian Journal of
Infectious Diseases 1989;21:543-9.
19. McCarthy PL, Frank AL, Ablow RC, Masters SJ, Dolan TF, Jr. Value of
the C-reactive protein test in the differentiation of bacterial and
viral pneumonia. The Journal of pediatrics 1978;92:454-6.
20. Salonen EM, Vaheri A. C-reactive protein in acute viral infections.
Journal of medical virology 1981;8:161-7.
21. Thompson D, Whicher JT, Banks RE. Acute phase reactants in
predicting disease outcome. Bailliere’s Clinical Rheumatology
1992;6:393-404.
22. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical
review. Pathology 1991;23:118-24.
23. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling,
immune modulation, antiviral response and virus countermeasures. Journal
of General Virology 2000;81:2341-64.
24. Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US
clinical trial to determine accuracy of FebriDx point-of-care testing
for acute upper respiratory infections with and without a confirmed
fever. Annals of medicine 2018;50:420-9.
25. Self WH, Rosen J, Sharp SC, et al. Diagnostic accuracy of FebriDx: a
rapid test to detect immune responses to viral and bacterial upper
respiratory infections. Journal of clinical medicine 2017;6:94.
26. Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP
point-of-care immunoassay to identify viral and/or bacterial immune
response in patients with acute febrile respiratory infection. European
clinical respiratory journal 2015;2:28245.
27. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and
potential vaccines: Lessons learned from SARS and MERS epidemic. Asian
Pacific J allergy Immunol 2020;10.
28. Tynell J, Westenius V, Rönkkö E, et al. Middle East respiratory
syndrome coronavirus shows poor replication but significant induction of
antiviral responses in human monocyte-derived macrophages and dendritic
cells. The Journal of general virology 2016;97:344.
29. The Centers for Disease Control and Prevention (CDC). Evaluating and
Testing Persons for Coronavirus Disease 2019 (COVID-19). Centers for
Disease Control and Prevention, 2020. (Accessed April 1, 2020, at
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html.)
30. The Centers for Disease Control and Prevention (CDC). Coronavirus
Disease 2019 (COVID-19): 2020 Interim Case Definition, Approved April 5,
2020 2020.
31. Public Health England (PHE). Guidance COVID-19: investigation and
initial clinical management of possible cases 2020.
32. Public Health England (PHE). Guidance COVID-19: investigation and
initial clinical management of possible cases 2020.
33. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of
procalcitonin-based guidelines vs standard guidelines on antibiotic use
in lower respiratory tract infections: the ProHOSP randomized controlled
trial. JAMA 2009;302:1059-66.
34. National Clinical Guideline C. Pneumonia: Diagnosis and management
of community and hospital acquired pneumonia in Adults. Clin Guidel
2014.
35. Docherty AB, Harrison EM, Green CA, et al. Features of 16,749
hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical
Characterisation Protocol. medRxiv 2020:2020.04.23.20076042.
36. Brendish NJ, Poole S, Naidu VV, et al. Real-World Diagnostic
Accuracy of a Host Response Point-of-Care Test in Hospitalised Patients
with Suspected COVID-19. Available at SSRN 3582747 2020.
37. Clark T, Brendish N. Evaluating the clinical impact of routine
molecular point-of-care testing for COVID-19 in adults presenting to
hospital: A prospective, interventional, non-randomised pre and post
implementation study (CoV-19POC)[Protocol]. 2020.
Table 1. Cohort Characteristics